Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The randomised, double-blind, placebo-controlled trial was conducted across 12 countries and enrolled 1206 adults with Type 2 diabetes, a body mass index (BMI) of at least 27, and HbA1c between 7% and 10%
Check documentation to ensure correct identification before beginning mixing steps
Unimolecular polypharmacy for treatment of diabetes and obesity
Data on common gastrointestinal side effects of different incretin-based therapies compared to placebo, pooled from other published systematic reviews and meta-analyses, highlights the lowest OR for nausea, vomiting, and diarrhoea with cagrilintide [Table 4].[22,24] Therefore, cagrilintide can be considered a promising therapeutic option for weight loss in obese individuals who may not tolerate GLP1RAs or have a lower tolerance for nausea and vomiting
doi: 10.1007/S00125-016-4067-4 43 BogdaniMKorposESimeonovicCJParishCRSorokinLWightTN
